Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.56 |
| ▸ | PDE4A | P27815 | 14/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669822 | 0.92 | PDE4B (0.54) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3675896 | 0.88 | PDE4B (0.57) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3672014 | 0.86 | PDE4B (0.60) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL5049520 | 0.85 | PDE4B (0.58) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3677039 | 0.85 | PDE4B (0.58) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3547203 | 0.84 | PDE4B (0.62) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3673495 | 0.84 | PDE4B (0.57) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3549331 | 0.83 | PDE4D (0.55) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3673682 | 0.83 | PDE4B (0.59) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3669273 | 0.83 | PDE4B (0.58) | PDE4BPDE4APDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048247-A1 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| EP-1869054-A2 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | Ranbaxy Laboratories Limited (IN) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006085212-A2 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048247-A1 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV | PDE3B, PDE4A, PDE3A | PDE4B 4/4885PDE4A 2/4885PDE4D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.